Recent Gallup data shows a decline in U.S. obesity rates, likely linked to widespread use of GLP-1 drugs like Ozempic and Wegovy.

People taking GLP-1 meds could see costs drop in 2026, thanks to a new federal deal with Eli Lilly and Novo Nordisk, the ...

Novo Nordisk A/S & Eli Lilly and Company cut prices for top diabetes drugs, boosting accessibility and potential revenue.

At a White House event Thursday, President Trump announced deals with drug makers Novo Nordisk and Eli Lilly to offer their ...

The latest move is set to cut costs of starting oral doses of GLP-1s to as low as around $150 for certain groups of people ...

Obesity products gain momentum in India and globally as multinationals leverage smart pricing and collaborations amidst ...

Danish diabetes and obesity drug giant Novo Nordisk has agreed with the US Administration to lower drug prices beginning in ...

The anti-obesity drug registered sales of ₹100 crore in October, unseating the previous best-selling antibiotic Augmentin, ...

Peptides are an important class of drugs. Almost 100 are approved as medicines, including insulin, human growth hormone and ...

Eli Lilly and Novo Nordisk have agreed pricing deals for GLP-1RA brands, a pivotal moment in the obesity treatment market.

Shares of Novo Nordisk are down 2.5% on Friday after the Trump administration announced agreements with the Danish drugmaker and Eli Lilly to cut prices for GLP-1 drugs used to treat diabetes and ...

The Trump administration’s pact with drugmakers to lower the price of GLP-1 drugs could pave the way for millions more to ...